Livmoniplimab
Drug timelines are a Plus or Pro feature.
5 regulatory and trial events tracked for Livmoniplimab, covering 2025-03-04 to 2026-02-23. Get the full timeline:
Most recent: Clinical Trial Update: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [Phase 2, Phase 3]